Celgene Primed For Growth Through 2017, Hugin Says At JPM
This article was originally published in The Pink Sheet Daily
Executive Summary
Celgene CEO Bob Hugin gave investors a taste of what’s to come for the biotech as it prepares for multiple NDA filings this year and the influx of data on several new indications for its lead drugs.